

Supplementary information

Heterogeneous magnitude of immunological memory to SARS-CoV-2 in recovered individuals
 Mazzone et al. 2021

Supplementary Table 1: Clinical features of study participants

	Case	Age	Gender	COVID-19 clinical presentation	Nasopharyngeal swab for SARS-CoV-2 (PCR) on March 2020	SARS-CoV-2 specific IgG on May 2020	Days from illness
Uninfected group	U1	66	M	asymptomatic	na	negative	-
	U2	54	M	asymptomatic	na	negative	-
	U3	26	M	asymptomatic	na	negative	-
	U4	39	M	asymptomatic	na	negative	-
	U5	27	M	asymptomatic	na	negative	-
	U6	55	M	asymptomatic	na	negative	-
	U7	61	M	asymptomatic	na	negative	-
	U8	36	M	asymptomatic	na	negative	-
	U9	37	M	asymptomatic	na	negative	-
	U10	32	M	asymptomatic	na	negative	-
	U11	37	M	asymptomatic	na	negative	-
	U12	51	M	asymptomatic	na	negative	-
	U13	21	M	asymptomatic	na	negative	-
	U14	37	M	asymptomatic	na	negative	-
Exposed group 1	EA1	33	M	asymptomatic	positive	positive	162
	EA2	50	M	asymptomatic	positive	positive	162
	EA3	60	M	asymptomatic	positive	positive	162
	EA4	22	M	mild	positive	positive	163
	EA5	56	M	mild	positive	positive	162
	EA6	35	M	mild	positive	positive	162
	EA7	34	M	mild	positive	positive	162
	EA8	36	M	mild	positive	positive	162
	EA9	53	M	mild	positive	positive	162
	EA10	66	M	mild	positive	positive	163
	EA11	25	M	mild	positive	positive	162
	EA12	20	M	mild	positive	positive	164
	EA13	56	M	moderate (hospitalized)	positive	positive	163
	EA14	44	M	moderate (hospitalized)	positive	positive	162
	EA15	39	M	severe (hospitalized)	positive	positive	162
Exposed group 2	EB1	55	M	asymptomatic	na	positive	na
	EB2	22	M	asymptomatic	na	positive	na
	EB3	23	M	asymptomatic	na	positive	na
	EB4	23	M	asymptomatic	na	positive	na

Supplementary information

Heterogeneous magnitude of immunological memory to SARS-CoV-2 in recovered individuals

Mazzoni et al. 2021

EB5	23	M	asymptomatic	na	positive	na
EB6	43	M	asymptomatic	na	positive	na
EB7	45	M	asymptomatic	na	positive	na
EB8	22	M	mild	na	positive	na
EB9	23	M	mild	na	positive	na
EB10	28	M	mild	na	positive	na
EB11	23	M	mild	na	positive	na
EB12	23	M	mild	na	positive	na
EB13	41	M	mild	na	positive	na
EB14	21	M	mild	na	positive	na
EB15	30	M	mild	na	positive	na

na: not available

Supplementary information

Heterogeneous magnitude of immunological memory to SARS-CoV-2 in recovered individuals


Mazzoni et al. 2021

Supplementary table 2. List of all fluoro-chrome mAbs used for flow cytometric analysis

Marker	Clone	Fluoro-chrome	Company
CD8	SK1	Super Bright 600	eBioscience™
CD3	SK7	PerCP	BDBioscience
CD4	SK3	PE-Cy™7	BDBioscience
CD154	TRAP1	PE	BDBioscience
IFN- γ	B27	Pacific Blue™	BioLegend
IL-2	MQ1-17H12	APC	BDBioscience
TNF- α	6401.1111	FITC	BDBioscience

Supplementary information

Heterogeneous magnitude of immunological memory to SARS-CoV-2 in recovered individuals
Mazzoni et al. 2021



Supplementary figure 1. Gating strategy for the identification of SARS-CoV-2 specific CD4+ T cells

Lymphocytes were identified based on physical parameters FSC-A and SSC-A. Live CD3+ T cells were subsequently gated using a viability dye (Live-Dead) and CD3. Single cells were then evaluated using FSC-A and FSC-H parameters. T helper cells were identified as CD4+CD8-. Among CD4+ T cells we identified recently activated cells based on CD154 expression. CD4+CD154+ were evaluated for the capacity to produce IFN- γ and TNF- α . All the four cell subsets defined by IFN- γ and TNF- α production were finally evaluated for their capacity to produce IL-2.